Old Web
English
Sign In
Acemap
>
authorDetail
>
Jaymes S Holland
Jaymes S Holland
AstraZeneca
Syk
Cancer research
relapsed refractory
Medicine
in patient
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
2021
Blood
Steven M. Horwitz
Tatyana Feldman
Jing C Ye
Michael S. Khodadoust
Javier Munoz
Paul A. Hamlin
Youn H. Kim
Ryan A. Wilcox
Manish R. Patel
Greg Coffey
Muhtarjan Osman
Jaymes S Holland
Cristina B Guzman
Sonali M. Smith
Show All
Source
Cite
Save
Citations (0)
Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
2021
Blood
Paul A. Hamlin
Manish R. Patel
Don A. Stevens
Brian T. Hess
Javier Munoz
Tatyana Feldman
Sonali M. Smith
Greg Coffey
Muhtarjan Osman
Jaymes S Holland
Cristina B Guzman
Stephen D. Smith
Show All
Source
Cite
Save
Citations (0)
1